FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 334:1178-1184 May 2, 1996 Number 18 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF Purchase this article Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Infections with parasitic helminths and protozoa are important causes of morbidity and mortality worldwide. Chemotherapy has an important role not only in the treatment of individual patients but also, in conjunction with public health and vector-control measures, in reducing the transmission of parasitic infections. At present, however, there are no vaccines for human parasitic infections, the scientific knowledge necessary to develop antiparasitic drugs is rudimentary, and the mechanisms of action of most antiparasitic drugs are poorly understood. Commercial incentives for the production of drugs designed to fight infections that are mainly endemic in developing countries are limited, and some proved . . . [Full Text of this Article]

Anthelmintic Drugs

Albendazole

            Echinococcosis

            Intestinal Tapeworms and Cysticercosis

            Intestinal Roundworms

            Other Roundworms

Ivermectin

            Onchocerciasis

            Other Filariases

            Other Roundworms

            Ectoparasites

Praziquantel

            Schistosomiasis

            Other Flukes

            Cestodes

Antiprotozoal Drugs

Albendazole

            Giardiasis

            Microsporidiosis

Fumagillin

            Ocular Microsporidiosis

Trimethoprim–Sulfamethoxazole

            Cyclosporiasis

            Isosporiasis

Paromomycin

            Cryptosporidiosis

Conclusions

Source Information

From the Department of Medicine, Harvard Medical School, and the Infectious Diseases Division, Beth Israel Hospital — both in Boston.

Address reprint requests to Dr. Weller at Beth Israel Hospital, DA-617, 330 Brookline Ave., Boston, MA 02215.

References

Related Letters:

Percutaneous Drainage of Hydatid Cysts
Schipper H. G., Kager P. A., Vasen W., Filice C., Brunetti E., Khuroo M. S.
Extract | Full Text  
N Engl J Med 1998; 338:391-393, Feb 5, 1998. Correspondence

This article has been cited by other articles:

• Pinlaor, S., Prakobwong, S., Hiraku, Y., Kaewsamut, B., Dechakhamphu, S., Boonmars, T., Sithithaworn, P., Pinlaor, P., Ma, N., Yongvanit, P., Kawanishi, S. (2008). Oxidative and Nitrative Stress in Opisthorchis viverrini-Infected Hamsters: An Indirect Effect after Praziquantel Treatment. Am J Trop Med Hyg 78: 564-573 [Abstract] [Full Text]  
• GELTMAN, P. L., COCHRAN, J., HEDGECOCK, C. (2003). INTESTINAL PARASITES AMONG AFRICAN REFUGEES RESETTLED IN MASSACHUSETTS AND THE IMPACT OF AN OVERSEAS PRE-DEPARTURE TREATMENT PROGRAM. Am J Trop Med Hyg 69: 657-662 [Abstract] [Full Text]  
• Baden, L. R., Elliott, D. D. (2003). Case 4-2003 - A 42-Year-Old Woman with Cough, Fever, and Abnormalities on Thoracoabdominal Computed Tomography. NEJM 348: 447-455 [Full Text]  
• Gardner, T. B., Hill, D. R. (2001). Treatment of Giardiasis. Clin. Microbiol. Rev. 14: 114-128 [Abstract] [Full Text]  
• White, A. C. (2000). The Disappearing Arsenal of Antiparasitic Drugs. NEJM 343: 1273-1274 [Full Text]  
• Schipper, H. G., Kager, P. A., Vasen, W., Filice, C., Brunetti, E., Khuroo, M. S. (1998). Percutaneous Drainage of Hydatid Cysts. NEJM 338: 391-393 [Full Text]  
• Cook, J., Reich, M. R., Nishioka, S. d. A., Liu, L. (1996). Case 4-1996: Paralysis Due to Schistosomiasis. NEJM 334: 1548-1549 [Full Text]